{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:26:17Z","timestamp":1758381977348,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.xphs.2022.01.031","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:00:26Z","timestamp":1643626826000},"page":"1058-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunochemical and biophysical characterization of inactivated Sabin poliovirus products: Insights into rapid quality assessment tools"],"prefix":"10.1016","volume":"111","author":[{"given":"Janny","family":"Westdijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Kogelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"van der Put","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-3110","authenticated-orcid":false,"given":"Zaskia","family":"Eksteen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon F.A.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-3979","authenticated-orcid":false,"given":"Maarten","family":"Danial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2022.01.031_bib0001","unstructured":"Global Wild Poliovirus 2015 - 2020. https:\/\/polioeradication.org\/wp-content\/uploads\/2020\/12\/weekly-polio-analyses-WPV-20201222.pdf. Accessed December 20, 2021."},{"key":"10.1016\/j.xphs.2022.01.031_bib0002","unstructured":"CDC - Progress Against Polio. https:\/\/www.cdc.gov\/polio\/progress\/index.htm. Accessed December 20, 2021."},{"issue":"10147","key":"10.1016\/j.xphs.2022.01.031_bib0003","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(18)30483-5","article-title":"On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine","volume":"392","author":"Peng","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.xphs.2022.01.031_bib0004","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6925a4","article-title":"Progress Toward Polio Eradication \u2014 Worldwide","volume":"69","author":"Chard","year":"2020","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.xphs.2022.01.031_bib0005","unstructured":"GPEI cVDVP Fact Sheet. https:\/\/polioeradication.org\/wp-content\/uploads\/2018\/07\/GPEI-cVDPV-Fact-Sheet-20191115.pdf. Accessed December 20, 2021."},{"issue":"41","key":"10.1016\/j.xphs.2022.01.031_bib0006","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.01.031_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2019.07.009","article-title":"New, less-expensive inactivated polio vaccine non-inferior to conventional inactivated vaccine","volume":"212","author":"Kreppel","year":"2019","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.031_bib0008","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: a progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"issue":"Supplement_2","key":"10.1016\/j.xphs.2022.01.031_bib0009","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: current production methods and new developments","volume":"6","author":"van Wezel","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.xphs.2022.01.031_bib0010","article-title":"Poliomyelitis vaccine (inactivated)","volume":"0215","year":"2012","journal-title":"Ph. Eur. 9.0"},{"issue":"45","key":"10.1016\/j.xphs.2022.01.031_bib0011","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.031_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a Phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.xphs.2022.01.031_bib0013","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 trial of a Sabin strain\u2013based inactivated poliovirus vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.031_bib0014","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1080\/21645515.2018.1504538","article-title":"A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children","volume":"14","author":"Nakano","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"39","key":"10.1016\/j.xphs.2022.01.031_bib0015","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.031_bib0016","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine: a phase 3 clinical trial","volume":"220","author":"Hu","year":"2019","journal-title":"J Infect Dis"},{"issue":"47","key":"10.1016\/j.xphs.2022.01.031_bib0017","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults","volume":"31","author":"Verdijk","year":"2013","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.xphs.2022.01.031_bib0018","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine"},{"issue":"15-16","key":"10.1016\/j.xphs.2022.01.031_bib0019","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0264-410X(98)00409-5","article-title":"Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains","volume":"17","author":"Kersten","year":"1999","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.xphs.2022.01.031_bib0020","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1016\/j.vaccine.2007.07.060","article-title":"Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains","volume":"25","author":"Tano","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.031_bib0021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.biologicals.2015.07.010","article-title":"Trypsin diminishes the rat potency of polio serotype 3","volume":"43","author":"ten Have","year":"2015","journal-title":"Biologicals"},{"issue":"17","key":"10.1016\/j.xphs.2022.01.031_bib0022","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2020.03.027","article-title":"Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats","volume":"38","author":"Murakami","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2022.01.031_bib0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4939-3292-4_16","article-title":"Measuring poliovirus antigenicity by surface plasmon resonance. Application for potency indicating assays","volume":"1387","author":"Westdijk","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.xphs.2022.01.031_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2019.113785","article-title":"Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines","volume":"276","author":"Kouiavskaia","year":"2020","journal-title":"J Virol Methods"},{"issue":"18","key":"10.1016\/j.xphs.2022.01.031_bib0025","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.031_bib0026","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/BA20040113","article-title":"Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry","volume":"41","author":"Krell","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.031_bib0027","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jps.23801","article-title":"Preformulation study of highly purified inactivated polio vaccine, serotype 3","volume":"103","author":"Qi","year":"2014","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.031_bib0028","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.xphs.2020.12.012","article-title":"Physicochemical characterization of sabin inactivated poliovirus vaccine for process development","volume":"110","author":"Torisu","year":"2021","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.031_bib0029","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.xphs.2022.01.031_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ab.2016.07.009","article-title":"Evaluation of calibration-free concentration analysis provided by Biacore\u2122 systems","volume":"510","author":"Pol","year":"2016","journal-title":"Anal Biochem"},{"year":"1985","series-title":"The Molecular Biology of Poliovirus","author":"Koch","key":"10.1016\/j.xphs.2022.01.031_bib0031"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.031_bib0032","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/js960475h","article-title":"Size and conformational stability of the hepatitis a virus used to prepare VAQTA\u22a5, a highly purified inactivated vaccine","volume":"86","author":"Volkin","year":"1997","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.01.031_bib0033","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0960-9822(00)00176-7","article-title":"Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design","volume":"4","author":"Grant","year":"1994","journal-title":"Curr Biol"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.031_bib0034","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1099\/0022-1317-71-6-1271","article-title":"Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus","volume":"71","author":"Ferguson","year":"1990","journal-title":"J Gen Virol"},{"issue":"24","key":"10.1016\/j.xphs.2022.01.031_bib0035","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.vaccine.2014.02.022","article-title":"Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods","volume":"32","author":"Thomassen","year":"2014","journal-title":"Vaccine"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:37:00Z","timestamp":1758361020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022354922000405"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.01.031","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunochemical and biophysical characterization of inactivated Sabin poliovirus products: Insights into rapid quality assessment tools","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}